Physician profile
Adam C Thomas
NPI 1437116530
$7,805.06
in general payments reported to CMS, 2019-2025
25 companies · $1,109 in 2025
The $1,109 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,220 · 2020: $140 · 2021: $193 · 2022: $1,292 · 2023: $1,121 · 2024: $1,730 · 2025: $1,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,352 · Travel and Lodging: $1,482 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,352.30 |
| Travel and Lodging | $1,482.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $4,215.42 | 2021-2025 | Urolift, Barrigel |
| Neotract INC. | $1,669.92 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $616.45 | 2023-2025 | Gemtesa |
| Procept Biorobotics Corporation | $369.08 | 2019 | |
| Astellas Pharma US INC | $130.81 | 2019 | |
| Pfizer INC. | $129.46 | 2019-2023 | |
| Boston Scientific Corporation | $93.08 | 2019-2025 | Axonics |
| Progenics Pharmaceuticals, INC. | $91.76 | 2023-2025 | Pylarify |
| Urogen Pharma, INC. | $83.77 | 2025 | |
| Fennec Pharmaceuticals, INC. | $54.77 | 2025 | Fyarro |
| Endo USA, INC. | $47.69 | 2024 | Xiaflex, Aveed |
| Laborie Medical Technologies Corp. | $44.72 | 2023-2024 | Optilume Bph Drug Coated Balloon Catheter |
| Ferring Pharmaceuticals INC. | $38.51 | 2025 | Adstiladrin |
| Abc Home Medical Supply, INC. | $32.11 | 2025 | |
| Blue Earth Diagnostics | $26.37 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $23.33 | 2020 | |
| Novartis Pharmaceuticals Corporation | $23.33 | 2025 | |
| Dendreon Pharmaceuticals LLC | $21.04 | 2019 | |
| Tolmar, INC. | $19.87 | 2025 | Jatenzo |
| Urovant Sciences INC | $16.30 | 2021 | |
| Horizon Therapeutics Plc | $14.10 | 2023 | Krystexxa |
| Olympus America INC. | $13.70 | 2023 | Itind System |
| Zyla Life Sciences, INC. | $12.95 | 2020 | |
| Clarus Therapeutics INC. | $11.50 | 2021 | |
| Healthtronics Stone Solutions, LLC | $5.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.